Evidence map›Paper›PMID 42244665›Full record

ArticlebioRxiv : the preprint server for biology2026

Pan-Cancer Genomic Scars of Alternative End Joining and Single-Strand Annealing.

Ashini Modi, Alessandro Zito, Giovanni Parmigiani

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ashini ModiHarvard College, Harvard University, Cambridge, MA, USA.
Alessandro ZitoDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0001-8515-6503
Giovanni ParmigianiDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Funding

Targeting Genomic Instability and Evolution in MyelomaP01CA155258 · NCI · DANA-FARBER CANCER INST · PI Jill Corre · 2011 to 2026
$32.5M
Statistical methods for cancer mutational signaturesR01CA262710 · NCI · DANA-FARBER CANCER INST · PI PARMIGIANI, GIOVANNI LUIGI · 2021 to 2025
$1.8M
NCI NIH HHS P01 CA155258NCI NIH HHS R01 CA262710
6 · The paper itself

Abstract

DNA double-strand breaks (DSBs) are among the most cytotoxic lesions encountered by cells and represent a major source of genome instability in cancer. The preferred pathway to repair resected DSBs is high-fidelity homologous recombination (HR), but error-prone annealing-dependent pathways such as single-strand annealing (SSA) and alternative end joining (Alt-EJ) generally act as backup repair mechanisms in HR-deficient contexts. However, the extent to which these pathways are engaged across tumor types and how their activity is coupled with HR deficiency remains unclear. In this work, we systematically characterize scars from SSA and Alt-EJ across 2,157 whole-genome-sequenced tumors spanning 17 cancer types, identifying 832 SSA-like and 37,359 Alt-EJ-like deletions in total. We find that Alt-EJ is the predominant backup repair pathway in HR-deficient tumors compared with SSA; however, prostate adenocarcinoma and hepatocellular carcinoma exhibit elevated SSA-like deletion burdens despite low HR-deficiency scores. Moreover, our genome-wide analysis reveals that SSA-like deletions preferentially occur in SINE-rich regions and exhibit pronounced enrichment near transcription start sites in HR-proficient lymphoid lineage tumors. Our results show that SSA- and Alt-EJ-associated genomic scars are not confined to HR-deficient tumors, but are shaped by local genomic and transcriptional context, capturing distinct dimensions of DSB repair activity beyond HR deficiency alone.

Identifiers

PMID42244665
PMCPMC13232104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.